BlossomHill Therapeutics (BLSM) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($461.2 million vs $454.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | STTK |
|---|---|---|
| Share price | $14.51 | $4.46 |
| Market cap | $461.20M | $454.22M |
| 1-day change | +0.69% | -1.98% |
| YTD return | — | +22.19% |
| 1-year return | — | +119.70% |
| 5-year return | — | -51.99% |
| EPS (TTM) | $-10.38 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.00M |
| Revenue growth (YoY) | — | -82.52% |
| Net income (latest FY) | — | $-48.81M |
| Operating margin | — | -5150.80% |
| Net margin | — | -4880.90% |
| 52-week high | $27.99 | $8.33 |
| 52-week low | $11.02 | $1.93 |
| Distance from 52-week high | -48.16% | -46.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +143.97% | +245.29% |
| Average volume | 193.15K | 1.20M |
| Shares outstanding | 31.78M | 101.84M |
| Employees | 69 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
BLSM vs STTK FAQ
Which is bigger, BlossomHill Therapeutics or Shattuck Labs?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $461.20M compared with $454.22M for Shattuck Labs (STTK).
Are BlossomHill Therapeutics and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.